Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Public ClinicalTrials.gov record NCT03907527. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/Ib Study Evaluating Safety and Efficacy of PRGN-3005 UltraCAR-T® (Autologous CAR T Cells) in Advanced Stage Platinum Resistant Ovarian Cancer Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen, Inc.) in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body, that has come back and is resistant to platinum chemotherapy. Autologous CAR T cells are modified immune cells that have been engineered in the laboratory to specifically target a protein found on tumor cells and kill them.
Study identification
- NCT ID
- NCT03907527
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 71 participants
Conditions and interventions
Conditions
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Refractory Fallopian Tube Carcinoma
- Refractory Ovarian Carcinoma
- Refractory Primary Peritoneal Carcinoma
- Stage III Fallopian Tube Cancer AJCC V8
- Stage III Ovarian Cancer AJCC V8
- Stage III Primary Peritoneal Cancer AJCC V8
- Stage IIIA Fallopian Tube Cancer AJCC V8
- Stage IIIA Ovarian Cancer AJCC V8
- Stage IIIA Primary Peritoneal Cancer AJCC V8
- Stage IIIA1 Fallopian Tube Cancer AJCC V8
- Stage IIIA1 Ovarian Cancer AJCC V8
- Stage IIIA2 Fallopian Tube Cancer AJCC V8
- Stage IIIA2 Ovarian Cancer AJCC V8
- Stage IIIB Fallopian Tube Cancer AJCC V8
- Stage IIIB Ovarian Cancer AJCC V8
- Stage IIIB Primary Peritoneal Cancer AJCC V8
- Stage IIIC Fallopian Tube Cancer AJCC V8
- Stage IIIC Ovarian Cancer AJCC V8
- Stage IIIC Primary Peritoneal Cancer AJCC V8
- Stage IV Fallopian Tube Cancer AJCC V8
- Stage IV Ovarian Cancer AJCC V8
- Stage IV Primary Peritoneal Cancer AJCC V8
- Stage IVA Fallopian Tube Cancer AJCC V8
- Stage IVA Ovarian Cancer AJCC V8
- Stage IVA Primary Peritoneal Cancer AJCC V8
- Stage IVB Fallopian Tube Cancer AJCC V8
- Stage IVB Ovarian Cancer AJCC V8
- Stage IVB Primary Peritoneal Cancer AJCC V8
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 29, 2019
- Primary completion
- Dec 14, 2024
- Completion
- Nov 14, 2028
- Last update posted
- Nov 7, 2024
2019 – 2028
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institutes of Health (NIH) | Bethesda | Maryland | 20892 | — |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03907527, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 7, 2024 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03907527 live on ClinicalTrials.gov.